PCSK9 Gain of Function Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About PCSK9 Gain of Function
PCSK9 gain of function is a genetic condition causing abnormally high levels of 'bad' LDL cholesterol, significantly raising the risk of heart disease and stroke. While targeted treatments can be life-changing, their cost often poses a challenge. TheDrugClub helps members afford these vital medications, ensuring access to necessary care for a healthier future.
Understanding PCSK9 Gain of Function
PCSK9 gain of function is a rare genetic condition that directly impacts your body's ability to clear LDL (low-density lipoprotein) cholesterol, often referred to as 'bad' cholesterol. At the heart of this condition is the PCSK9 gene, which produces a protein that regulates the number of LDL receptors on the surface of liver cells. These receptors are crucial for removing LDL cholesterol from the bloodstream.
In individuals with PCSK9 gain of function, a specific mutation in this gene causes the PCSK9 protein to be overactive. This overactivity leads to the premature degradation of LDL receptors, meaning fewer receptors are available to do their job. The result? LDL cholesterol accumulates in the blood, leading to very high levels that significantly increase the risk of atherosclerosis (hardening of the arteries), heart attacks, and strokes, often at a younger age than typically expected.
Common Treatments and Medications
Managing PCSK9 gain of function primarily involves lowering LDL cholesterol to reduce cardiovascular risk. While statins are often the first line of defense for high cholesterol, their effectiveness can be limited in cases of PCSK9 gain of function due to the underlying genetic mechanism. For these patients, a class of medications known as PCSK9 inhibitors has proven highly effective.
These injectable medications, such as alirocumab (Praluent) and evolocumab (Repatha), work by blocking the PCSK9 protein. By inhibiting PCSK9, these drugs prevent the destruction of LDL receptors, allowing more receptors to remain active and remove excess LDL cholesterol from the blood. This can lead to dramatic reductions in LDL levels, significantly improving patient outcomes. However, these breakthrough treatments often come with a substantial price tag, making them difficult for many to afford, even with insurance.
How TheDrugClub Members Save on Prescriptions
This is where TheDrugClub steps in. We understand that managing a condition like PCSK9 gain of function requires consistent access to often expensive medications. For a simple monthly membership fee—with a Drug Club membership—TheDrugClub provides access to significant discounts on thousands of prescription drugs, including many high-cost specialty
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.